Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
company focused on the discovery and development of novel therapeutic
candidates that engage the body’s ability to rebuild and repair its own
cells and tissues, today announced that senior management will
participate in two upcoming healthcare investor conferences in May.

Conference Details:

Live audio webcasts for both conferences will be available on the
« Events and Presentations » page in the Investors section on the
Company’s website (www.acceleronpharma.com).
A replay of the webcasts will also be available on Acceleron’s website.

About Acceleron

Acceleron discovers and develops novel therapies to treat a wide range
of rare diseases. Its pioneering research platform leverages the
powerful biology behind the body’s ability to rebuild and repair its own
cells and tissues. This innovative approach to drug discovery has
generated four therapeutic candidates currently in clinical trials. The
Company’s lead therapeutic candidate, luspatercept, is being evaluated
in Phase 3 studies for the treatment of the hematologic diseases
myelodysplastic syndromes (MDS) and beta-thalassemia under a global
partnership with Celgene Corp. Acceleron is also advancing clinical
programs in the fields of oncology and neuromuscular diseases and has a
comprehensive preclinical research effort targeting fibrotic and other
serious diseases.

For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426006846/en/